Drug
PD1 Inhibitor
CI-DRUG-00000432Explore in graph →NCIt C124946 CIViC
Regulatory
Approvals (0)
Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.
Data not yet available
No regulatory approval recorded. Absence here is not evidence of absence: only ingested jurisdictions are covered.
What CancerIndex knows
Derived
Development pipeline
Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.
| Scope | Stage | Max phase | Active | Recruiting | Phase 3 | Trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| All cancers | Phase2 | Phase 2 | 2 | 1 | 0 | 5 | 0 | — | — | Apr 26, 2021 |
| Malignant Gastric Neoplasm | Phase2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | May 1, 2025 |
| Malignant Lung Neoplasm | Phase2 | Phase 2 | 1 | 1 | 0 | 3 | 0 | — | — | Apr 26, 2021 |
| Malignant Breast Neoplasm | Phase2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Jul 19, 2021 |
| Malignant Esophageal Neoplasm | Phase2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — |
Curated evidence
Clinical evidence (6)
CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-10
- Retrieved
- Sep 10, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 29467336
- Run
- ING-CIVIC-20260910-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| High3 | ||||||||
| PD1 Inhibitor | Head and Neck Squamous Cell Carcinoma | |||||||
Clinical trials
Trials with this intervention (6)
Most recently updated first, 50 per page.
clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Dataset
- ClinicalTrials.gov API v2 studies
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04093323 | Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma | terminated | Phase 2 | 1 | Roswell Park Cancer InstituteOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT06896422 | Randomized Trial of Glutathione With Anti-PD-1 and Chemotherapy in Advanced NSCLC | recruiting |